Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -133.74 Million SEK | 0.07% |
| 2022 | -133.9 Million SEK | -59.05% |
| 2021 | -84.19 Million SEK | -72.29% |
| 2020 | -48.86 Million SEK | -34.13% |
| 2019 | -36.43 Million SEK | -36.13% |
| 2018 | -26.76 Million SEK | -105.46% |
| 2017 | -13.02 Million SEK | -38.4% |
| 2016 | -9.41 Million SEK | -23.87% |
| 2015 | -7.59 Million SEK | -20.65% |
| 2014 | -6.29 Million SEK | -10.66% |
| 2013 | -5.69 Million SEK | -28.76% |
| 2012 | -4.41 Million SEK | -109.17% |
| 2011 | -2.11 Million SEK | 6.39% |
| 2010 | -2.25 Million SEK | -38.55% |
| 2009 | -1.62 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -33.86 Million SEK | -0.67% |
| 2024 Q2 | -34.52 Million SEK | -2.53% |
| 2023 Q4 | -33.63 Million SEK | -10.63% |
| 2023 FY | -133.81 Million SEK | 0.07% |
| 2023 Q1 | -31.42 Million SEK | 27.24% |
| 2023 Q2 | -35.07 Million SEK | -11.63% |
| 2023 Q3 | -30.4 Million SEK | 13.32% |
| 2022 Q3 | -32.9 Million SEK | 19.5% |
| 2022 Q4 | -43.18 Million SEK | -31.26% |
| 2022 FY | -133.9 Million SEK | -59.05% |
| 2022 Q2 | -40.87 Million SEK | -95.0% |
| 2022 Q1 | -20.96 Million SEK | 13.86% |
| 2021 Q3 | -19.68 Million SEK | 12.72% |
| 2021 Q1 | -17.62 Million SEK | -13.42% |
| 2021 FY | -84.19 Million SEK | -72.29% |
| 2021 Q2 | -22.55 Million SEK | -27.97% |
| 2021 Q4 | -24.33 Million SEK | -23.62% |
| 2020 Q3 | -11.74 Million SEK | 11.93% |
| 2020 Q1 | -9.4 Million SEK | 1.35% |
| 2020 FY | -48.86 Million SEK | -34.13% |
| 2020 Q4 | -15.53 Million SEK | -32.24% |
| 2020 Q2 | -13.34 Million SEK | -41.78% |
| 2019 Q3 | -8.23 Million SEK | 10.06% |
| 2019 FY | -36.43 Million SEK | -36.13% |
| 2019 Q2 | -9.15 Million SEK | 3.73% |
| 2019 Q1 | -9.5 Million SEK | 15.77% |
| 2019 Q4 | -9.53 Million SEK | -15.86% |
| 2018 Q4 | -11.28 Million SEK | -93.49% |
| 2018 FY | -26.76 Million SEK | -105.46% |
| 2018 Q2 | -5.54 Million SEK | -35.24% |
| 2018 Q1 | -4.09 Million SEK | -11.63% |
| 2018 Q3 | -5.83 Million SEK | -5.27% |
| 2017 FY | -13.02 Million SEK | -38.4% |
| 2017 Q4 | -3.67 Million SEK | -49.59% |
| 2017 Q3 | -2.45 Million SEK | 16.25% |
| 2017 Q2 | -2.93 Million SEK | 26.18% |
| 2017 Q1 | -3.96 Million SEK | -11.11% |
| 2016 Q4 | -3.57 Million SEK | -81.97% |
| 2016 FY | -9.41 Million SEK | -23.87% |
| 2016 Q3 | -1.96 Million SEK | 3.01% |
| 2016 Q2 | -2.02 Million SEK | -9.3% |
| 2016 Q1 | -1.85 Million SEK | -2.01% |
| 2015 Q3 | -1.98 Million SEK | 8.53% |
| 2015 Q4 | -1.81 Million SEK | 8.42% |
| 2015 Q1 | -1.63 Million SEK | 1.38% |
| 2015 FY | -7.59 Million SEK | -20.65% |
| 2015 Q2 | -2.16 Million SEK | -32.69% |
| 2014 Q1 | -1.34 Million SEK | -17.63% |
| 2014 FY | -6.29 Million SEK | -10.66% |
| 2014 Q2 | -1.9 Million SEK | -40.97% |
| 2014 Q3 | -1.39 Million SEK | 26.72% |
| 2014 Q4 | -1.65 Million SEK | -18.92% |
| 2013 FY | -5.69 Million SEK | -28.76% |
| 2013 Q3 | -1.08 Million SEK | 38.12% |
| 2013 Q1 | -1.74 Million SEK | -67.43% |
| 2013 Q4 | -1.14 Million SEK | -5.98% |
| 2013 Q2 | -1.74 Million SEK | 0.0% |
| 2012 FY | -4.41 Million SEK | -109.17% |
| 2012 Q4 | -1.04 Million SEK | 0.0% |
| 2011 FY | -2.11 Million SEK | 6.39% |
| 2010 FY | -2.25 Million SEK | -38.55% |
| 2009 FY | -1.62 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -72.456% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 144.493% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 144.493% |
| Arcoma AB | 4.66 Million SEK | 2970.064% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | -1.373% |
| BICO Group AB (publ) | -618.3 Million SEK | 78.369% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 440.578% |
| CellaVision AB (publ) | 167.05 Million SEK | 180.062% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -102.85% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -352.276% |
| C-Rad AB (publ) | 44.24 Million SEK | 402.29% |
| Duearity AB (publ) | -25.76 Million SEK | -419.136% |
| Dignitana AB (publ) | -15.02 Million SEK | -790.091% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -41.081% |
| Getinge AB (publ) | 3.81 Billion SEK | 103.507% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -95.403% |
| Iconovo AB (publ) | -45.77 Million SEK | -192.168% |
| Integrum AB (publ) | 6.51 Million SEK | 2153.716% |
| Luxbright AB (publ) | -25.8 Million SEK | -418.302% |
| Mentice AB (publ) | -679 Thousand SEK | -19597.349% |
| OssDsign AB (publ) | -91.95 Million SEK | -45.445% |
| Paxman AB (publ) | 12.61 Million SEK | 1159.87% |
| Promimic AB (publ) | -9.11 Million SEK | -1366.824% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 20.719% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -147.956% |
| ScandiDos AB (publ) | -13.48 Million SEK | -891.953% |
| Sectra AB (publ) | 518.49 Million SEK | 125.795% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -104.044% |
| SpectraCure AB (publ) | -21.35 Million SEK | -526.411% |
| Stille AB | 44.95 Million SEK | 397.528% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 96.273% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 447.335% |